IMImmutep Limited IMMP · NASDAQ
$3.20 -0.31% (-$0.01)
- Market cap
- $33.8M
- Enterprise value
- -$34.0M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 2.4x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -118.2%
- Gross margin
- 83.0%
- Net margin
- -544.8%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 2.31
- Free float
- 97.1%
About the company
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987, and is headquartered in Sydney, Australia.
Sector
Healthcare
Industry
Biotechnology
CEO
Marc Voigt
Employees
53
Headquarters
Sydney
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number